F10 and hemophilia: A 2022 review on hemophilia by Payne et al. summarizing evidence from three pharmacokinetic studies (TEN01, TEN02, TEN05) and real-life evidence from case reports and case series, provides specific suggestions regarding the administration and dosage of plasma-derived FX, as well as the monitoring of FX levels [36].